Skip to content

Author

A. Mostaghimi

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Baricitinib Efficacy Through 4 Years in Responders and Safety up to 5 Years in Adults with Severe Alopecia Areata: Final Results from BRAVE-AA1 and BRAVE-AA2

Long-term efficacy and safety data are imperative for therapies used to treat severe alopecia areata (AA) because the disease is chronic, loss of response can be devastating to patients, and the safety profile needs to support long-term therapy. Baricitinib, a selective JAK inhibitor, has been approved for severe AA in...

R. Vleugels, B. M. Piraccini, N. Mesinkovska et al. · 0 citations
Open access Sep 2026

Dose optimization of deuruxolitinib in adults with alopecia areata: A phase 2 randomized trial.

BACKGROUND The autoimmune disorder alopecia areata (AA) results in patchy or complete hair loss. OBJECTIVE To evaluate the efficacy and safety of the Janus kinase 1/2 inhibitor deuruxolitinib dosed 8 mg twice daily (BID) or 16 mg once daily (QD) in adults with severe AA. METHODS In this phase 2 study (NCT03811912),...

Brett King, Steven Kempers, N. Mesinkovska et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.